News | August 26, 2014

New Study First to Examine Quality of Cardiac Rehabilitation Programs in Canada

August 26, 2014 — The quality of cardiac rehabilitation programs across Canada is strong, with specific criteria areas now identified as requiring further enhancement to improve patient outcomes, according to a new study conducted by researchers at the Peter Munk Cardiac Center, York University and the University Health Network (UHN).

“We are the first to comprehensively assess cardiac rehabilitation quality—what we are doing well and where we should do better—to this degree across the country,” said Sherry Grace, M.D., study author and director of research, GoodLife Fitness Cardiovascular Rehabilitation Unit, University Health Network, and York University kinesiology and health science professor. “Being able to rigorously evaluate and compare across cardiac rehabilitation programs nationally means gaps can be addressed and changes made, to ultimately benefit patients who have heart disease.”

Set to be published in the Canadian Journal of Cardiology, the study measured 14 key quality indicators in 10 cardiac rehabilitation programs across Canada, assessing more than 5,500 cardiac patients. The criteria examined included: accessibility, wait times, referrals, secondary prevention, behavior changes and psychosocial measures.

“Recovery from a heart attack, open-heart surgery or other related procedures improves substantially when a patient participates fully in a cardiac rehabilitation program,” said Barry Rubin, M.D., Ph.D., FRCSC, medical director, Peter Munk Cardiac Center. “With tens of thousands of new patients across Canada being treated for heart disease each year, it is imperative that patients participate in the program of exercise and education that form the basis for cardiac rehab as part of their recovery, to prevent their risk of experiencing another serious cardiac event. This leading-edge study makes that goal more attainable.”

The study found that cardiac rehabilitation programs are successful in: assessing patients’ body composition (85 percent), measuring blood pressure (90 percent), increasing exercise capacity (68 percent) and offering cessation therapy to patients who smoke (61 percent). Areas requiring improvement included: measuring blood sugar in patients with diabetes (23 percent) and assessment of depression (13 percent).

Research has shown that heart patients who engage in cardiac rehab are 25 percent less likely to die, than patients who do not participate in cardiac rehab. At the same time, only about 30 percent of heart patients who are hospitalized and who qualify to participate in a cardiac rehab program actually do so.

The United States and Europe have also developed some quality indicators for cardiac rehab. Canada is the first country to nationally assess program quality.

The study was funded in part by the BRIDGE project managed by the Canadian Cardiovascular Society and funded by the Public Health Agency of Canada.

For more information: www.petermunkcardiaccentre.ca


Related Content

News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
News | Cardiovascular Clinical Studies

Jan. 13, — A new cohort study among 103,642 adults found that current use of cigars was associated with increased risk ...

Home January 14, 2025
Home
News | Cardiovascular Clinical Studies

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...

Home November 25, 2024
Home
News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
Subscribe Now